Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.

Trimble CL, Peng S, Thoburn C, Kos F, Wu TC.

Cancer Immunol Immunother. 2010 May;59(5):799-803. doi: 10.1007/s00262-009-0806-4. Epub 2009 Dec 13.

2.

Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D, Kos F, Teague J, Jiang Y, Barat NC, Jungbluth AA.

J Immunol. 2010 Dec 1;185(11):7107-14. doi: 10.4049/jimmunol.1002756. Epub 2010 Oct 29.

3.

Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.

Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH.

J Natl Cancer Inst. 1997 Sep 3;89(17):1285-93.

PMID:
9293919
4.

T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.

Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.

Clin Vaccine Immunol. 2010 Sep;17(9):1315-21. doi: 10.1128/CVI.00105-10. Epub 2010 Jul 28.

5.

T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.

de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ.

J Gen Virol. 1996 Sep;77 ( Pt 9):2183-91.

PMID:
8811018
6.

Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.

Jiang B, Xue M.

Genet Mol Res. 2015 Sep 8;14(3):10473-81. doi: 10.4238/2015.September.8.8.

7.

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, Welters MJ, van Poelgeest MI, Melief CJ, Kenter GG, van der Burg SH.

Cancer Immunol Immunother. 2012 Sep;61(9):1485-92. doi: 10.1007/s00262-012-1292-7. Epub 2012 Jun 9.

8.

Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.

van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH.

Int J Cancer. 2006 Feb 1;118(3):675-83.

9.

CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.

Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M.

Cancer Immunol Immunother. 2012 Jan;61(1):63-70. doi: 10.1007/s00262-011-1092-5. Epub 2011 Aug 13.

10.

Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.

Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.

Exp Mol Pathol. 2012 Feb;92(1):185-90. doi: 10.1016/j.yexmp.2011.10.002. Epub 2011 Oct 15.

PMID:
22032938
11.

Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression.

Øvestad IT, Gudlaugsson E, Skaland I, Malpica A, Kruse AJ, Janssen EA, Baak JP.

Mod Pathol. 2010 Sep;23(9):1231-40. doi: 10.1038/modpathol.2010.109. Epub 2010 May 28.

12.

Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.

Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M; Albert Einstein Cervix Dysplasia Clinical Consortium.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):483-8.

13.

Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.

Tong WW, Shepherd K, Garland S, Meagher A, Templeton DJ, Fairley CK, Jin F, Poynten IM, Zaunders J, Hillman RJ, Grulich AE, Kelleher AD, Carr A; Study of the Prevention of Anal Cancer (SPANC) team.

J Infect Dis. 2015 Feb 1;211(3):405-15. doi: 10.1093/infdis/jiu461. Epub 2014 Aug 19.

PMID:
25139018
14.

Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, van der Zee AG, Daemen T.

Clin Exp Immunol. 2007 Nov;150(2):199-209.

15.

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL.

Gynecol Oncol. 2016 Feb;140(2):245-52. doi: 10.1016/j.ygyno.2015.11.026. Epub 2015 Nov 23.

16.

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH.

Cancer Res. 2004 Aug 1;64(15):5449-55.

17.

Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.

Vintermyr OK, Iversen O, Thoresen S, Quint W, Molijn A, de Souza S, Rosillon D, Holl K.

Gynecol Oncol. 2014 May;133(2):159-66. doi: 10.1016/j.ygyno.2014.03.004. Epub 2014 Mar 11.

PMID:
24631451
18.

Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.

de Vos van Steenwijk PJ, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, Hellebrekers BW, Kenter GG, van der Burg SH.

Clin Cancer Res. 2008 Nov 15;14(22):7188-95. doi: 10.1158/1078-0432.CCR-08-0994.

19.

The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3.

Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, Baak JP.

J Clin Pathol. 2011 Apr;64(4):303-7. doi: 10.1136/jcp.2010.083626.

PMID:
21421698
20.

Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions.

Lee BN, Follen M, Rodriquez G, Shen DY, Malpica A, Shearer WT, Reuben JM.

Cancer. 2006 Sep 1;107(5):999-1007.

Supplemental Content

Support Center